



#10

Attorney Docket: GENO200.2/CIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	PAGRATIS <i>et al.</i>	}	
SERIAL NO.:	09/363,939		EXAMINER: ZITOMER, S.
FILED:	JULY 29, 1999		ART UNIT: 1655
FOR:	HIGH AFFINITY TGF β NUCLEIC ACID LIGANDS AND INHIBITORS		

STATEMENT UNDER 37 C.F.R. § 1.821(f)

Assistant Commissioner for Patents
Box SEQUENCE
Washington, D. C. 20231


Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed August 26, 2002, enclosed is a computer readable form of the SEQUENCE LISTING for the above-identified application submitted under 37 C.F.R. § 1.821(e). Also enclosed is a paper copy of the SEQUENCE LISTING under 37 C.F.R. § 1.821(c).

I hereby state that the contents of the disk and the paper copy are the same. 37 C.F.R. § 1.821(f).

The paper and disk copies of the SEQUENCE LISTING include no new matter. 37 C.F.R. § 1.821(g).

Respectfully submitted,


Margaret M. Wall, #33,462
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
(303) 268-0066

S:\Client Folders\Evolutionary Genomics\200-2\CIP2\Sequence Statement 03.doc

37 CFR 1.8

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231 on 9/26/02

Signature: _____

Name: Tasha L. Cove